About Us


Company Overview

ROX® Medical has developed an implantable device and therapy intended to treat uncontrolled high blood pressure. Blood pressure reduction is achieved by diverting a small amount of blood flow from the arterial system into the venous system.

The ROX Coupler is a small stent-like device that is placed between the artery and vein located in the upper thigh. The Coupler is about the size of a dime and is easily placed using standard catheter techniques.

ROX Medical is conducting the CONTROL HTN-2 clinical trial in the United States for hypertension (visit www.controlhtn2.com for more information). The ROX Medical Coupler is commercially available in Europe under CE mark.


Management Team

Rodney Brenneman, CEO and President

Rodney Brenneman has 24 years of experience in the medical device industry. He co-founded ROX Medical in 2004. Prior to ROX Medical Mr. Brenneman worked for USGI Medical as Vice President of R&D. At USGI he led a team of nine engineers and technicians to develop devices for endo-luminal GI surgery. Mr. Brenneman co-founded TheraCardia in 1998 and served as VP of R&D and Operations until 2003. Prior to 1998, Mr. Brenneman worked for Vesica Medical, acquired by Boston Scientific, Corp in 1996 and Advanced Surgical Intervention acquired by Boston Scientific, Corp in 1993. Mr. Brenneman has also done considerable consulting for very early stage medical device companies in a wide variety of specialties including Cardiology, Orthopedics, Urology, Opthamology, Neurology and Interventional Radiology.

Paul Sobotka, MD, Chief Scientific Officer

Paul Alan Sobotka, M.D., F.A.C.C., F.A.C.P., F.A.H.A., Chief Medical Officer of ROX, Inc. Graduated from Stanford University with degree in Chemistry and obtained his Medical Degree from the University of Illinois College of Medicine. Dr. Sobotka completed training in Internal Medicine at The University of Michigan, followed by specialty training in cardiovascular diseases at Northwestern University.  He holds an appointment as Clinical Professor of Medicine/Cardiology at The Ohio State University.

Dr. Sobotka has authored nearly 200 peer reviewed manuscripts and book chapters including manuscripts published in: The Journal Clinical Investigation, American Journal of Physiology, The New England Journal of Medicine, Circulation: The Lancet, Circulation: Heart Failure, Journal of Congestive Failure, Hypertension, Journal of Hypertension, Journal of the American Society of Nephrology, and Journal of Congestive Heart Failure.

Charles Love, Sr. Vice President of Global Clinical Operations and Regulatory Affairs

Charles “Chuck” Love is the Senior Vice President of Global Clinical Operations and Regulatory Affairs. Chuck has held a variety of senior executive roles for both large a small medical device companies. Prior to joining ROX Medical Chuck served as Vice President of Clinical Affairs at Endologix where he and his team managed the clinical evidence program involving more 3,000 patients in active clinical studies. Chuck led the clinical team at CoreValve prior to its acquisition by Medtronic, and then worked with Medtronic on the integration of CoreValve and subsequent acquisition and integration of ATS Medical. He has founded two medical device companies in the structural heart space, and is an active board member including Loma Vista Medical which was successfully acquired by CR Bard. Chuck received his B.A. in Biology from Westmont College. He also completed undergraduate work in Engineering at Gonzaga University and completed management programs at the University of California and Stanford University. He holds numerous patents, is published in peer-reviewed journals, and has presented original data at major medical society meetings.

David Pozzi, Senior Director, Clinical & Procedural Development

David Pozzi is the Senior Director of Clinical & Procedure Development at ROX Medical.  David has held leadership positions in the medical device industry over the past 20 years. Prior to joining ROX, David worked at Endologix as the  Director of Clinical Outcomes, managing the clinical field operations team for the company’s global clinical trials.  In addition to the field responsibilities, he  developed and managed training programs for the clinical sites, optimizing study processes and outcomes. David has a demonstrated history of leadership in clinical operations, clinical management, and global training development in the medical device industry  with roles at Guidant, Boston Scientific, and Alcon Laboratories. David earned his Bachelors of Science degree from the University of Oregon.


Peter Balmforth, Director of Therapy Development, Education, and Sales

Peter Balmforth is the Director of Therapy Development, Education and Sales for Europe. Bringing 10 years of medical device experience,  Peter joined ROX Medical in 2010 to lead the European market. Prior to ROX, he was Country Manager for both Atritech and Ablation Frontiers, both exited in successful mergers with BSX and Medtronic. Previously he served as Territory Manager for Endocardial Solutions, Inc., and post acquisition by St. Jude Medical, he continued his service as Product Manager.


Chris Yelley, Director of Operations

Chris Yelley is the Director of Operations for ROX Medical. With over 30 years of experience in the medical device industry Chris joined ROX Medical in 2008 to lead the manufacturing and operations efforts. Prior to joining ROX Medical Chris was with ev3 Neurovascular where he led the Process Development team. From 2000 through 2005 Chris served as Vice President of Operations with IntraLuminal Therapeutics in Carlsbad, CA. He has lead operations, quality, engineering and manufacturing teams both nationally and internationally, developing lean and efficient processes and programs for, MRI Interventions, Intravascular Research Limited and Advanced Cardiovascular Systems (Guidant).

roxmedicalusAbout Us